Real-World Kidney Cancer Insights from 10 Key Cities
This is an excerpt from the blog “Uneven Terrain: How Local Real-World Insights Can Improve Kidney Cancer Outcomes” by Komodo Health. The Kidney Cancer Association partners with Komodo Health, an AI-powered life sciences company uncovering the complex factors that contribute to the patient journey. Read the detailed report: “Uneven Terrain: Using Real-World Evidence to Understand Regional Differences in Kidney Cancer”.
Nearly 81,000 Americans will be newly diagnosed with kidney cancer this year, and incidence has continued to rise over the past two decades. But national statistics only tell part of the story. A patient’s experience with kidney cancer — when it’s diagnosed, how advanced it is, and how many providers are able to diagnose and treat it — can look very different depending on where they live.
Understanding these local differences is essential for improving patient outcomes. Strategies that work well in one region may fall short in another if they don’t account for variations in disease burden, patient demographics, or healthcare capacity.
To better understand these dynamics, Komodo Health has partnered with the Kidney Cancer Association (KCA) during National Kidney Awareness Month to examine kidney cancer across 10 major U.S. metropolitan areas (Atlanta, GA; Bay Area, CA; Chicago, IL; Dallas/Fort Worth, TX; Durham-Chapel Hill, NC; Houston, TX; New York City, NY; Philadelphia, PA; Phoenix, AZ; Seattle, WA). This analysis used Komodo’s healthcare-native AI analytics platform, Marmot™.
Where disease burden and system capacity diverge
The analysis revealed meaningful differences across metropolitan areas in both disease burden and healthcare capacity.
Rates of kidney cancer in these areas varied widely, ranging from approximately 123 cases per 100,000 people in Seattle to nearly 202 per 100,000 in Phoenix. Several West Coast metro areas, including the Bay Area and Seattle, exhibited a disproportionately high share of metastatic disease within their kidney cancer population. In these regions, more than 22% of patients were diagnosed with metastatic kidney cancer, compared with the national rate of 18.4%, with increases across age groups.
Patient age distributions also differed by region. In Atlanta, pediatric patients accounted for up to 1.8% of cases, higher than the metro average of 1.2%. In cities such as Chicago, Phoenix, and Durham-Chapel Hill, patients age 65 and older made up more than two-thirds of all cases.
In parallel, diagnostic capacity did not always track with disease burden. Some large metros combined lower metastatic shares with higher patient-to-provider ratios. For example, New York City had an average of 1.4 kidney cancer patients per diagnosing provider versus 1.1 across large metros, suggesting differences in diagnostic capacity and care pathways.
From the report:
Key Findings
- Kidney cancer prevalence ranged widely across U.S. metropolitan areas, from ~123 per 100K in Seattle to ~202 per 100K in Philadelphia.
- West Coast metros, particularly the Bay Area and Seattle, showed metastatic rates well above the national average.
- New York City had the highest patient-to-provider ratio among metros (1.4 vs. 1.1).
- Higher shares of pediatric kidney cancer patients were seen in Atlanta and Seattle, and higher shares of young adult patients (ages 25-44) in Dallas/Fort Worth, Houston, and Seattle.
Executive Summary
Nearly 81,000 Americans will be newly diagnosed with kidney cancer this year, and incidence has continued to rise over the past two decades. Rates vary considerably across the U.S., shaped by population characteristics, environmental and lifestyle factors, and access to timely care.
National rates often obscure the realities patients face locally. Real-world evidence (RWE) makes these differences visible — revealing where disease burden is highest, where advanced disease is more common, and where diagnostic capacity may be under strain. This level of geographic specificity is foundational for shaping effective advocacy, outreach, and institutional partnerships. The findings reveal distinct regional profiles of kidney cancer burden, metastatic disease, and provider patient-to-provider ratio, highlighting areas where targeted advocacy, education, and system-level interventions may yield the greatest benefit.
This blog highlights an important point that kidney cancer can vary greatly depending on location, healthcare access, and early diagnosis. Understanding these regional differences can help improve awareness, treatment, and patient outcomes. Many people ignore kidney-related symptoms until the condition becomes serious, so articles like this are very useful for educating the public about the importance of timely care and regular screenings Best kidney clinic in raichur.